IDT.AU · IDT Australia Limited

-

Please sign in to comment on IDT.AU

1 Comment

Admin

4 years, 1 month ago

IDT Australia Limited is currently in a long term uptrend where the price is trading 25.5% above its 200 day moving average.

From a valuation standpoint, the stock is 96.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.2.

IDT Australia Limited's total revenue sank by 19.5% to $6M since the same quarter in the previous year.

Its net income has increased by 195.0% to $1M since the same quarter in the previous year.

Finally, its free cash flow grew by 107.9% to $118K since the same quarter in the previous year.

Based on the above factors, IDT Australia Limited gets an overall score of 4/5.

ISIN	AU000000IDT0
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Exchange	AU
CurrencyCode	AUD

Beta	1.25
Market Cap	49M
PE Ratio	None
Target Price	0.08
Dividend Yield	None

ABOUT

IDT Australia Limited

IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the Unites States. and internationally. It offers microbiological and analytical testing, clinical packaging, and pharmacy services. The company also provides medicinal cannabis and psychedelics; oral finished doses; and aseptic fill and finish solutions for liquid and lyophilised forms. In addition, it offers mRNA and ADCs. Further, the company provides contract manufacturing services. IDT Australia Limited was founded in 1975 and is headquartered in Boronia, Australia.

IDT.AU · IDT Australia Limited

-

IDT Australia Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest IDT Australia Limited using a moving average strategy